Amarin Stock Forecast, Price & News

-0.10 (-2.43 %)
(As of 07/23/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume2.71 million shs
Average Volume3.05 million shs
Market Capitalization$1.59 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter.

Amarin logo

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.72 out of 5 stars

Medical Sector

264th out of 2,214 stocks

Pharmaceutical Preparations Industry

121st out of 867 stocks

Analyst Opinion: 3.2Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Amarin (NASDAQ:AMRN) Frequently Asked Questions

Is Amarin a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Amarin stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRN, but not buy additional shares or sell existing shares.
View analyst ratings for Amarin
or view top-rated stocks.

What stocks does MarketBeat like better than Amarin?

Wall Street analysts have given Amarin a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amarin wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Amarin's next earnings date?

Amarin is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Amarin

How can I listen to Amarin's earnings call?

Amarin will be holding an earnings conference call on Thursday, August 5th at 7:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 877-481-4010 with passcode "401474".

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) issued its quarterly earnings data on Wednesday, February, 24th. The biopharmaceutical company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.01) by $0.02. The biopharmaceutical company had revenue of $165.90 million for the quarter, compared to analyst estimates of $164.21 million. Amarin had a trailing twelve-month return on equity of 0.15% and a net margin of 0.15%. The business's revenue for the quarter was up 15.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.04 EPS.
View Amarin's earnings history

How has Amarin's stock been impacted by COVID-19?

Amarin's stock was trading at $12.56 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AMRN shares have decreased by 68.0% and is now trading at $4.02.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AMRN?

7 analysts have issued 1-year price objectives for Amarin's stock. Their forecasts range from $5.00 to $19.00. On average, they anticipate Amarin's share price to reach $10.33 in the next twelve months. This suggests a possible upside of 157.0% from the stock's current price.
View analysts' price targets for Amarin
or view top-rated stocks among Wall Street analysts.

Who are Amarin's key executives?

Amarin's management team includes the following people:
  • Mr. John F. Thero, Pres, CEO & Director (Age 60, Pay $1.37M)
  • Mr. Michael W. Kalb, CFO, Sr. VP & Assistant Sec. (Age 50, Pay $656.66k)
  • Dr. Steven B. Ketchum, Pres of R&D, Sr. VP and Chief Scientific Officer (Age 56, Pay $758.14k)
  • Mr. Joseph T. Kennedy, Exec. VP, Gen. Counsel & Strategic Initiatives and Sec. (Age 53, Pay $762.77k)
  • Mr. Aaron D. Berg, Sr. VP & Chief Commercial Officer (Age 58, Pay $656.09k)
  • Ms. Elisabeth Schwartz, Sr. Director of Investor Relations
  • Mr. Daniel S. Dunham, Sr. VP & Chief Pharmaceutical Compliance Officer
  • Alina Kolomeyer, Director of Communications
  • Mr. Rami Daoud, Sr. VP of Corp. Devel.
  • Ms. Donna Pasek, Sr. VP of HR

What is John Thero's approval rating as Amarin's CEO?

10 employees have rated Amarin CEO John Thero on John Thero has an approval rating of 93% among Amarin's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Amarin's key competitors?

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), (CGC), Square (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX).

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

Who are Amarin's major shareholders?

Amarin's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Brookstone Capital Management (0.00%). Company insiders that own Amarin stock include David M Stack, John F Thero, Lars Ekman and Steven B Ketchum.
View institutional ownership trends for Amarin

Which institutional investors are buying Amarin stock?

AMRN stock was acquired by a variety of institutional investors in the last quarter, including Brookstone Capital Management.
View insider buying and selling activity for Amarin
or or view top insider-buying stocks.

How do I buy shares of Amarin?

Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $4.02.

How much money does Amarin make?

Amarin has a market capitalization of $1.59 billion and generates $614.06 million in revenue each year. The biopharmaceutical company earns $-18,000,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis.

How many employees does Amarin have?

Amarin employs 1,000 workers across the globe.

What is Amarin's official website?

The official website for Amarin is

Where are Amarin's headquarters?

Amarin is headquartered at 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2.

How can I contact Amarin?

Amarin's mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at 353-1669-9020 or via email at [email protected]

This page was last updated on 7/25/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.